Skip to content

Perfusion Pressure Cerebral Infarction Trial (PPCI)

The Importance of Mean Arterial Pressure During Cardiopulmonary Bypass to Prevent Cerebral Complications After Cardiac Surgery - a Randomised Clinical Trial.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02185885
Acronym
PPCI
Enrollment
197
Registered
2014-07-10
Start date
2014-07-31
Completion date
2016-04-30
Last updated
2016-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Embolic Stroke, Postoperative Cognitive Dysfunction

Keywords

Ischemic stroke, Embolic stroke, Postoperative Cognitive Dysfunction, Cardiac Bypass Surgery, Cardiac Anaesthesia

Brief summary

STUDY HYPOTHESIS In cardiac surgery the volume of perioperative cerebral infarctions can be reduced by increasing mean arterial pressure (MAP) during the cardiopulmonary bypass procedure. BRIEF STUDY SUMMARY Heart surgery using cardiopulmonary bypass (CPB) can be complicated by injury to the brain. Previous studies using brain scans have reported small stroke-like lesions in up to 51% of patients after cardiac surgery. However, only 1-6 % of patients have permanent symptoms of severe brain damage. The majority of brain lesions seem to be caused by particulate matter (emboli) that wedge in blood vessels of the brain thereby compromising flow. In addition, insufficient blood flow to areas of the brain supplied by narrowed, calcified vessels may contribute. MAP during CPB usually stabilizes below the lower limit of cerebral autoregulation, which is accepted since sufficient total blood flow is guaranteed during CPB. The aim of the PPCI trial is to investigate if increased MAP during CPB can prevent or reduce the extent of brain injury after cardiac surgery. A beneficial effect could result from reduced embolic injury through increased blood flow in collateral vessels and/or by increased blood flow in calcified arteries. 180 patients scheduled for cardiac surgery will be randomly allocated to increased MAP (70-80 mm Hg) or 'usual practice' (typically 45-50 mm Hg) during CPB, whereas CPB blood flow is intended equal and fixed in the two groups. Patients are examined before and 3-6 days after surgery with magnetic resonance imaging (MRI) brain scans, mental tests and by blood borne markers of brain injury. If higher MAP during CPB is beneficial, a change of practice can easily be implemented in the clinical routine.

Detailed description

TRIAL DESIGN The PPCI trial is a randomized, controlled, outcomes assessor and patient blinded, single-center superiority trial with two parallel groups in a 1:1 allocation ratio. The randomization will be stratified according to age (stratum 1 \< 70 years; stratum 2 ≥ 70 years) and type of surgery (stratum 1 - surgery involving the aortic and/or mitral valve; stratum 2 - surgery not involving these valves).

Interventions

PROCEDUREIncreased bloodpressure during CPB.

Sponsors

Danish Heart Foundation
CollaboratorOTHER
Rigshospitalet, Denmark
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥ 18 years of age. * scheduled elective or subacute cardiac surgery with the use of CPB. * type of surgery either coronary artery bypass grafting (CABG) and/or heart valve surgery (provided that the valve prosthesis used is MRI compatible).

Exclusion criteria

* a history of stroke. * a history of reversible ischemic deficits (duration of symptoms 24-72 hours) * a history of transitory ischemic attacks (duration of symptoms \< 24 hours) * diagnosis of neurodegenerative disorders such as Alzheimers, Multiple Sclerosis etc.

Design outcomes

Primary

MeasureTime frameDescription
Total volume of new ischemic cerebral lesions6 daysThe total volume of new ischemic cerebral lesions (sum in mL) assessed by diffusion-weighed-magnetic resonance imaging conducted preoperatively and again once postoperatively on day 3 to 6. The analysis will be adjusted for the randomization stratification variables age and type of surgery.

Secondary

MeasureTime frameDescription
Total number of new ischemic cerebral lesions6 daysThe total number of new ischemic cerebral lesions (sum in mL) assessed by diffusion-weighed-magnetic resonance imaging conducted preoperatively and again once postoperatively on day 3 to 6.
Magnetic resonance spectroscopy - change from baseline N-acetylaspartate-creatine (NAA/Cr) ratio at day 66 daysDiffuse cerebral injury is investigated using Single-Voxel Magnetic Resonance Spectroscopy (MRS) in grey and white cerebral matter and expressed as the difference in N-acetylaspartate-creatine (NAA/Cr) ratio between a scan conducted preoperatively and one conducted postoperatively on day 3 to 6.
Magnetic resonance spectroscopy - change from baseline MRS Choline-creatine (Cho/Cr ratio) at day 66 daysDiffuse cerebral injury is investigated using Single-Voxel Magnetic Resonance Spectroscopy (MRS) in grey and white cerebral matter and expressed as the difference in Choline-creatine (Cho/Cr ratio) between a scan conducted preoperatively and one conducted postoperatively on day 3 to 6.
Postoperative cognitive dysfunction (POCD) - change from baseline neuropsychological test performance at day 5-85-8 daysThe presence of cognitive dysfunction is evaluated preoperatively and on day 5-8 using the following collection of specific tests each time: Visual Verbal Learning test, Concept Shifting test, Stroop Colour Word Interference test and Letter Digit Coding test. Cognitive dysfunction is defined as a deterioration corresponding to a Z-score \> 2 (as defined by the ISPOCD group).
Peak value of biochemical markers of brain injuryPrior to surgery on day 1 and 24 hours, 48 hours and 6 days after surgeryBlood samples will be drawn at 4 different time points during the admission. Serum concentration and time course of the following markers of brain injury will be assessed: Phosphorylated Neurofilament Heavy Protein (pNfH), Glial Fibrillary Acidic Protein (GFAP), Matrix Metallopeptidase 9 (MMP-9) and Ubiquitin C-terminal Hydrolase 1 (UCH-L1).
Near Infrared Spectroscopy (NIRS) - lowest valueEnd of surgeryNear Infrared Spectroscopy (NIRS) NIRS values from the right and left frontal lobes of the brain will be continuously monitored during the intraoperative period and saved for later analysis. The NIRS monitor will be hidden and muted during the procedure.
Near Infrared Spectroscopy (NIRS) - total time below 25% of the baseline value on right and left sideEnd of surgeryNear Infrared Spectroscopy (NIRS) NIRS values from the right and left frontal lobes of the brain will be continuously monitored during the intraoperative period and saved for later analysis. The NIRS monitor will be hidden and muted during the procedure.
Change from baseline performance at neurological examination day 66 daysNew neurological deficits are assessed by performing an objective, clinical neurological examination.
Postoperative cognitive dysfunction (POCD) - change from baseline neuropsychological test performance at 3 months3 monthsThe presence of cognitive dysfunction is evaluated preoperatively and 3 months postoperatively using the following collection of specific tests each time: Visual Verbal Learning test, Concept Shifting test, Stroop Colour Word Interference test and Letter Digit Coding test. Cognitive dysfunction is defined as a deterioration corresponding to a Z-score \> 2 (as defined by the ISPOCD group).

Other

MeasureTime frameDescription
GAMPT BCC200 countEnd of cardiopulmonary bypass procedureThe GAMPT BCC200 is integrated into the heart-lung-machine (HLM), and through the use of ultrasound Doppler techniques, detection of gaseous micro-emboli (GME, volume between 5-500 µl) is enabled. The system can be used to quantify the GME that pass from the HLM into the bloodstream of the patient.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026